";s:4:"text";s:4209:"Coherus is a leading global biosimilar company. REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its United States manufacturing and distribution is well positioned to ensure uninterrupted availability of UDENYCA ® for patients. REDWOOD CITY, Calif., July 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q1 2020 Results - Earnings Call Transcript May.
Coherus BioSciences Production Exceeds Four-Hundred Thousand UDENYCA® (pegfilgrastim-cbqv) Pre-Filled SyringesCoherus uses cookies on this website. Catch the big one: Coherus BioSciences could launch a biosimilar to Humira, the world's most successful drug product, in July 2023, but it needs to complete various manufacturing … “Coherus provides unencumbered choice of pegfilgrastim product to patients and providers in Coherus estimates that over 200 American jobs are directly attributed to the production of UDENYCA“I want to congratulate the Coherus Operations Team and our manufacturing partners on achieving this significant milestone,” commented Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to Coherus’ expectations regarding its ability to produce up to one million UDENYCAPlease click the links below to download PDF versions of the following documents: REDWOOD CITY, Calif., July 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date.“Coherus provides unencumbered choice of pegfilgrastim product to patients and providers in the United States," said Denny Lanfear, President and CEO of Coherus. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Process and Manufacturing. Bundled rebate contracts for biologic brands that are designed to thwart biosimilar competition in the US are anti-competitive practices that deserve Federal Trade Commission action, biosimilar developer Coherus’ chief argues in a newspaper opinion piece.
